Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Chromatin remodeling/DNA methylation
Synonyms [1]

MRE11 meiotic recombination 11 homolog A (MRE11) is a gene that encodes a nuclear protein that functions in homologous recombination, the maintenance of telomere length, and DNA double-strand break repair. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

MRE11A is altered in 1.30% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].

MRE11A GENIE Cases - Top Diseases

The most common alterations in MRE11A are MRE11A Mutation (0.93%), MRE11A Amplification (0.11%), MRE11A Loss (0.12%), MRE11A Nonsense (0.09%), and MRE11A R633Q (0.02%) [3].

MRE11A GENIE Cases - Top Alterations

Significance of MRE11A in Diseases

Malignant Solid Tumor +

Breast Carcinoma +

Prostate Adenocarcinoma +

Ovarian Carcinoma +

Prostate Carcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Small Cell Lung Carcinoma +

Non-Small Cell Lung Carcinoma +

Gastric Carcinoma +

Pancreatic Adenocarcinoma +

Endometrial Carcinoma +

Melanoma +

Colorectal Carcinoma +

Cervical Carcinoma +

Soft Tissue Sarcoma +

Pancreatic Carcinoma +

Head And Neck Carcinoma +

Urothelial Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Squamous Cell Lung Carcinoma +

Non-Hodgkin Lymphoma +

Gastric Adenocarcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Esophageal Carcinoma +

Gastrointestinal Stromal Tumor +

Osteosarcoma +

Penile Carcinoma +

Pancreatic Ductal Adenocarcinoma +

Mantle Cell Lymphoma +

Malignant Uterine Neoplasm +

Medulloblastoma +

Rhabdomyosarcoma +

Neuroblastoma +

Anal Carcinoma +

Malignant Intestinal Neoplasm +

Colorectal Adenocarcinoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Lung Carcinoma +

Malignant Central Nervous System Neoplasm +

Bladder Carcinoma +

Bladder Urothelial Carcinoma +

Malignant Small Intestinal Neoplasm +

Glioma +

Cancer +

Esophageal Squamous Cell Carcinoma +

Malignant Mesothelioma +

Malignant Esophagogastric Neoplasm +

Ewing Sarcoma +

Esophageal Adenocarcinoma +

Clear Cell Renal Cell Carcinoma +

Diffuse Large B-Cell Lymphoma +

Malignant Ovarian Epithelial Tumor +

Malignant Gastric Neoplasm +

Multiple Myeloma +

B-Cell Non-Hodgkin Lymphoma +

Bile Duct Adenocarcinoma +

Bile Duct Carcinoma +

Cholangiocarcinoma +

Invasive Breast Carcinoma +

Biliary Tract Carcinoma +

Leiomyosarcoma +

Gallbladder Carcinoma +

Ampulla Of Vater Carcinoma +

Bronchogenic Carcinoma +

Low Grade Ovarian Serous Adenocarcinoma +

Ovarian Clear Cell Adenocarcinoma +

Vaginal Carcinoma +

Vulvar Carcinoma +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.